Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ERBB2 pos PIK3CA act mut||uterine cancer||sensitive||Taselisib||Preclinical||Actionable||In a preclinical study, Taselisib (GDC-0032) inhibited growth of HER2 positive uterine cancer cell lines with PIK3CA mutations (PMID: 25172762).||25172762|
|ERBB2 pos PIK3CA act mut||Her2-receptor positive breast cancer||decreased response||Trastuzumab||Clinical Study - Cohort||Actionable||In a clinical study, ERBB2 (HER2)-positive breast cancer patients with PI3K pathway activation resulting from low PTEN expression and/or PIK3CA activating mutations demonstrated decreased progression-free survival following treatment with Herceptin (trastuzumab) compared to patients without PI3K pathway activation (PMID: 17936563).||17936563|
|ERBB2 pos PIK3CA act mut||Her2-receptor positive breast cancer||decreased response||Trastuzumab||Clinical Study - Cohort||Actionable||In a retrospective analysis, ERBB2 (HER2)-positive breast cancer patients with PI3K pathway activation due to PTEN loss and/or PIK3CA activating mutation demonstrated a decreased median progression-free survival of 4.5 months, compared to 9.0 months for patients without PI3K pathway activation following treatment with a Herceptin (trastuzumab) containing regimen (PMID: 21676217).||21676217|
|ERBB2 pos PIK3CA act mut||Her2-receptor positive breast cancer||predicted - sensitive||Buparlisib + Trastuzumab||Phase I||Actionable||In a Phase I trial, the combination of Buparlisib (BKM120) and Herceptin (trastuzumab) was well tolerated and resulted in some preliminary efficacy in patients with ERBB2 (HER2)-positive breast cancer harboring PIK3CA activating mutations and/or PTEN mutations that had progressed on trastuzumab-based therapy (PMID: 24470511).||24470511|
|ERBB2 pos PIK3CA act mut||Her2-receptor positive breast cancer||sensitive||Palbociclib + Pictilisib||Preclinical||Actionable||In a preclinical study, Ibrance (palbociclib) and Pictilisib (GDC-0941) worked synergistically to inhibit survival of ERBB2 (HER2)-positive breast cancer cell lines harboring PIK3CA mutations in culture (PMID: 27020857).||27020857|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|